‌

US Patent 7674791 Triazolopyrazines and methods of making and using the same

Patent 7674791 was granted and assigned to Biogen on March, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Gang Yao0

Gnanasambandam Kumaravel0

Hairuo Peng0

Hexi Chang0

James E. Dowling0

Jeffrey Vessels0

Russell C. Petter0

Date of Patent

March 9, 2010

0

Patent Application Number

105523050

Date Filed

April 9, 2004

0

Patent Citations Received

US Patent 11999740 Fused pyrazine derivatives as A2A / A2B inhibitors

0

US Patent 11673894 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

0

US Patent 11873304 Fused pyrimidine derivatives as A2A/A2B inhibitors

0

US Patent 11884665 Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors

0

Patent Primary Examiner

James O. Wilson

0

Patent abstract

The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula on paper copy)

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7674791 Triazolopyrazines and methods of making and using the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.